FLT3 and leukemia: We next determined the effect of SNDX-5613 on in vivo leukemia-initiating potential of primary PD AML cells harboring MLL-AF9 plus FLT-3 N676T, as well as mutations in KMT2C, KMT2D, NOTCH2, IRF8, ARID1A, VPS13A, and ABCA7, which were determined by whole-exome sequencing (Table S1).